Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Surgical Innovations Group plc (SUN.L)
Leeds, GB
Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precision engineering applications. Its global presence extends across the UK, Europe, the Asia Pacific region, and the United States. The company operates through three distinct divisions: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment is responsible for the research, development, production, and commercialization of its proprietary SI-branded minimally invasive instruments. Key products within this portfolio include the YelloPort Elite and YelloPort +plus laparoscopic port access systems, LogiRange resposable laparoscopic instrument systems, FastClamp laparoscopic clamping systems, and QuickRange single-use laparoscopic instrumentation. The OEM division focuses on crafting and supplying minimally invasive devices for third-party medical device firms, often under their own brand or through co-branding arrangements. This segment also provides comprehensive design and development solutions for creating final medical devices and is involved in the research, development, manufacturing, and sale of minimally invasive technology tailored for precision engineering. Lastly, the Distribution segment handles the supply of various medical products, primarily via its subsidiary, Elemental Healthcare Ltd, and also designs and produces autologous blood products. Surgical Innovations Group plc sells its offerings through a network of independent healthcare distributors, while its own-label products are also distributed through its OEM collaborations.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +5.56% | +5.56% | -17.39% | +5.56% | -32.14% | -78.89% | -85.82% | -74.67% | -98.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-2.9% Q4'25: -14.3% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+52.4% ★ Q4'25: -900.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+5.7% Q4'25: +14.1% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-6.3% Q4'25: -14.5% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-9.8% Q4'25: -40.0% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: -1.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-9.11× Q4'25: -0.38× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.47M
est: 13.00M (-57.9%)
|
6.09M
est: 6.18M (-1.5%)
|
8.75M
est: 8.70M (+0.6%)
|
10.97M
est: 11.00M (-0.3%)
|
10.73M
est: 10.63M (+1.0%)
|
6.33M
est: 6.10M (+3.7%)
|
9.13M
est: 9.09M (+0.4%)
|
11.34M
est: 11.29M (+0.4%)
|
12.01M
est: 11.87M (+1.2%)
|
11.95M
est: 12.40M (-3.7%)
|
11.60M
est: 11.46M (+1.3%)
|
12.40M
12.40M – 12.40M
+8.2% YoY
|
| EBITDA |
-1.05M
est: -675.3K (-54.7%)
|
1.41M
est: -321.1K (+538.8%)
|
1.99M
est: -451.9K (+539.4%)
|
2.24M
est: -571.3K (+492.5%)
|
-1.17M
est: -552.2K (-112.6%)
|
-2.20M
est: -316.9K (-593.6%)
|
247.0K
est: -472.4K (+152.3%)
|
628.0K
est: -586.7K (+207.0%)
|
161.0K
est: -616.7K (+126.1%)
|
-99.0K
est: 201.5K (-149.1%)
|
-73.0K
est: 186.2K (-139.2%)
|
201.5K
201.5K – 201.5K
+8.2% YoY
|
| EBIT |
-1.97M
est: -1.98M (+0.2%)
|
470.0K
est: -939.5K (+150.0%)
|
410.0K
est: -1.32M (+131.0%)
|
620.0K
est: -1.67M (+137.1%)
|
-2.43M
est: -1.62M (-50.7%)
|
-3.17M
est: -927.1K (-241.8%)
|
-455.0K
est: -1.38M (+67.1%)
|
41.0K
est: -1.72M (+102.4%)
|
-596.0K
est: -1.80M (+67.0%)
|
-1.95M
est: -799.0K (-144.2%)
|
-731.0K
est: -738.2K (+1.0%)
|
-799.0K
-799.0K – -799.0K
-8.2% YoY
|
| Net Income |
-2.03M
est: 7.74M (-126.3%)
|
716.0K
est: 746.3K (-4.1%)
|
626.0K
est: 1.36M (-54.1%)
|
725.0K
est: 1.53M (-52.6%)
|
-2.62M
est: 447.8K (-684.9%)
|
-3.28M
est: -1.91M (-71.9%)
|
-456.0K
est: -260.3K (-75.2%)
|
264.0K
est: -18.7K (+1,515.1%)
|
-509.0K
est: -542.9K (+6.2%)
|
-1.94M
est: -250.9K (-674.3%)
|
-895.0K
est: -700.5K (-27.8%)
|
-307.8K
-307.8K – -307.8K
+56.1% YoY
|
| SGA |
482.0K
est: 3.15M (-84.7%)
|
668.0K
est: 1.50M (-55.4%)
|
1.49M
est: 2.11M (-29.3%)
|
2.45M
est: 2.66M (-8.1%)
|
2.58M
est: 2.57M (+0.4%)
|
2.01M
est: 1.48M (+36.4%)
|
2.13M
est: 2.20M (-3.3%)
|
2.42M
est: 2.73M (-11.6%)
|
2.63M
est: 2.87M (-8.6%)
|
2.71M
est: 3.02M (-10.3%)
|
3.78M
est: 2.79M (+35.6%)
|
3.02M
3.02M – 3.02M
+8.2% YoY
|
| EPS |
0.00
est: 0.01 (-150.6%)
|
0.00
est: 0.00 (+87.5%)
|
0.00
est: 0.00 (-45.3%)
|
0.00
est: 0.00 (-45.2%)
|
0.00
est: 0.00 (-787.5%)
|
0.00
est: 0.00 (-90.9%)
|
0.00
est: 0.00 (-79.2%)
|
0.00
est: 0.00 (+1,600.0%)
|
0.00
est: 0.00 (+14.1%)
|
0.00
est: 0.00 (-680.7%)
|
0.00
est: 0.00 (-33.2%)
|
0.00
0.00 – 0.00
+56.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David John Marsh | Chief Executive Officer & Director | 224.0K | male |
| Brent Raymond Greetham | Chief Financial Officer, Company Secretary & Director | — | male |
| Damian Donnelly | Chief Commercial Officer | — | male |
| Julia Horrocks Taylor | HR Director | — | — |
| Stephen Seed | Chief Compliance Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SUN.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
